{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:49:08Z","timestamp":1778237348233,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Veritas Pharma Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cannabis contains \u0394<jats:sup>9<\/jats:sup>-tetrahydrocannabinol (\u0394<jats:sup>9<\/jats:sup>-THC) and cannabidiol (CBD) as the primary constituents responsible for pharmacological activity. However, there are numerous additional chemically-related structures to \u0394<jats:sup>9<\/jats:sup>\u2013THC and CBD that are pharmacologically active and may influence the pharmacological properties of \u0394<jats:sup>9<\/jats:sup>-THC and CBD. This study chemically characterized the cannabinoid constituents in a series of cannabis chemovar extracts and investigated the potential cannabinoid entourage effect in two behavioral assays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Six chemovar extracts were compared to pure \u0394<jats:sup>9<\/jats:sup>-THC, CBD and morphine for effects on the following behavioral assays in mice: hot plate and tail suspension. The battery of behavioral tests was conducted post intravenous administration of cannabis chemovar extract. Cannabinoid profiles of extracts were analyzed using high performance liquid chromatography. Cannabis extracts were administered at equal doses of \u0394<jats:sup>9<\/jats:sup>-THC to investigate the role of their cannabinoid profiles in modulating the effects of \u0394<jats:sup>9<\/jats:sup>-THC. Dose response curves were fit using a log[inhibitor] vs response three parameter model and differences between group means were determined using a one-way ANOVA followed by a post hoc test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cannabis chemovars tested in this study exhibited substantially different cannabinoid profiles. All chemovars produced dose-dependent immobility in the tail suspension assay and dose-dependent antinociception in the hot plate assay. The maximum antinociceptive effect and ED50 was comparable between cannabis chemovars and \u0394<jats:sup>9<\/jats:sup>-THC. Two cannabis chemovars produced significantly greater immobility in the tail suspension test, with no significant differences in ED50.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Commercially available cannabis chemovars vary widely in cannabinoid content, but when equalized for \u0394<jats:sup>9<\/jats:sup>-THC content, they produce similar behavioral effects with two exceptions. These findings provide only limited support for the entourage hypothesis. Further studies are necessary to characterize the nature of these pharmacological differences between cannabis chemovars and pure \u0394<jats:sup>9<\/jats:sup>-THC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42238-020-00026-0","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T11:02:44Z","timestamp":1589194964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A pharmacological characterization of Cannabis sativa chemovar extracts"],"prefix":"10.1186","volume":"2","author":[{"given":"Alykhan","family":"Devsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theophile","family":"Ouellette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Hegle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo E.","family":"Rivera-Acevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Pugsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9513-1713","authenticated-orcid":false,"given":"Timothy","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"26_CR1","unstructured":"Anon (2018). Cannabis act. Minister of Justice, Health Canada. https:\/\/laws-loisjusticegcca\/eng\/acts\/C-245\/ Access date: 14 Oct 2019."},{"key":"26_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13722-015-0032-7","volume":"10","author":"KA Belendiuk","year":"2015","unstructured":"Belendiuk KA, Baldini LL, Bonn-Miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:10.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"26_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/09540261.2018.1474730","volume":"30","author":"MO Bonn-Miller","year":"2018","unstructured":"Bonn-Miller MO, ElSohly M, Loffin MJE, Chandra S, Vandrey R. Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. Int Rev Psychiatry. 2018;30(3):277\u201384.","journal-title":"Int Rev Psychiatry"},{"key":"26_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/phar.1187","volume":"33","author":"LM Borgelt","year":"2013","unstructured":"Borgelt LM, Franson KL, Nussbaum AM, et al. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33:195\u2013209.","journal-title":"Pharmacotherapy"},{"key":"26_CR5","first-page":"621","volume":"5","author":"LA Borgen","year":"1973","unstructured":"Borgen LA, Lott GC, Davis WM. Cannabis-induced hypothermia: a dose-effect comparison of crude marihuana extract and synthetic 9 -tetrahydrocannabinol in male and female rats. Res Commun Chem Pathol Pharmacol. 1973;5:621\u20136.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"26_CR6","first-page":"587","volume":"257","author":"DA Brase","year":"1991","unstructured":"Brase DA, Ward CR, Tripathi HL, et al. An insulin-independent mechanism of intrathecal morphine-induced hypoglycemia in mice: mediation through a central alpha-2 adrenergic pathway. J Pharmacol Exp Ther. 1991;257:587\u201394.","journal-title":"J Pharmacol Exp Ther"},{"key":"26_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/can.2018.0030","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Kight R. Regulatory status of cannabidiol in the United States: a perspective. Cannabis Cannabinoid Res. 2018;3:190\u20134.","journal-title":"Cannabis Cannabinoid Res"},{"key":"26_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","volume":"29","author":"JF Cryan","year":"2005","unstructured":"Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005;29:571\u2013625.","journal-title":"Neurosci Biobehav Rev"},{"key":"26_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0022-2828(87)80585-0","volume":"19","author":"BA Curtis","year":"1987","unstructured":"Curtis BA, MacLeod BA, Walker MJA. Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J Mol Cell Cardiol. 1987;19:399\u2013419.","journal-title":"J Mol Cell Cardiol"},{"key":"26_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bph.14153","volume":"175","author":"MJ Curtis","year":"2018","unstructured":"Curtis MJ, Alexander S, Cirino G, et al. Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br J Pharmacol. 2018;175:987\u201393.","journal-title":"Br J Pharmacol"},{"key":"26_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello, et al. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163:1479\u201394.","journal-title":"Br J Pharmacol"},{"key":"26_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1124\/jpet.107.134809","volume":"325","author":"L De Petrocellis","year":"2008","unstructured":"De Petrocellis L, Vellani V, Schiano-Moriello A, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther. 2008;325:1007\u201315.","journal-title":"J Pharmacol Exp Ther"},{"key":"26_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jat.727","volume":"21","author":"KH Diehl","year":"2001","unstructured":"Diehl KH, Hull R, Morton D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 2001;21:15\u201323.","journal-title":"J Appl Toxicol"},{"key":"26_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bcp.12920","volume":"81","author":"M Eddleston","year":"2016","unstructured":"Eddleston M, Cohen AF, Webb DJ. Implications of the BIA-102474-101 study for review of first-into-human clinical trials. Br J Clin Pharmacol. 2016;81:582\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"26_CR15","first-page":"385","volume":"107","author":"NB Eddy","year":"1953","unstructured":"Eddy NB, Leimbach D. Synthetic analgesics. II Dithienyl-butenyl dithienbutylamine. J Pharmacol Exp Ther. 1953;107:385\u201393.","journal-title":"J Pharmacol Exp Ther"},{"key":"26_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","volume":"95","author":"AT El-Alfy","year":"2010","unstructured":"El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav. 2010;95:434\u201342.","journal-title":"Pharmacol Biochem Behav"},{"key":"26_CR17","first-page":"269","volume":"123","author":"E Fride","year":"2006","unstructured":"Fride E, Perchuk A, Hall FS, et al. Behavioral methods in cannabinoid research. Methods Mol Med. 2006;123:269\u201390.","journal-title":"Methods Mol Med"},{"key":"26_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00213-005-2242-2","volume":"181","author":"M Haney","year":"2005","unstructured":"Haney M, Rabkin J, Gunderson E, et al. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology. 2005;181:170\u20138.","journal-title":"Psychopharmacology"},{"key":"26_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.irn.2018.07.006","volume":"140","author":"L Hood","year":"2018","unstructured":"Hood L. Social factors and animal models of cannabis use. Int Rev Neurobiol. 2018;140:171\u2013200.","journal-title":"Int Rev Neurobiol"},{"key":"26_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/3-540-26573-2_23","volume":"168","author":"MA Huestis","year":"2005","unstructured":"Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2005;168:657\u201390.","journal-title":"Handb Exp Pharmacol"},{"key":"26_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1254\/jjp.21.411","volume":"21","author":"H Kaneto","year":"1971","unstructured":"Kaneto H, Nakanishi H. A simple quantitative method for the evaluation of physical dependence liability of morphine in mice. Jpn J Pharmacol. 1971;21:411\u20133.","journal-title":"Jpn J Pharmacol"},{"key":"26_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/1574884711666160418105339","volume":"11","author":"R Kaur","year":"2016","unstructured":"Kaur R, Ambwani SR, Singh S. Endocannabinoid system: a multi-facet therapeutic target. Curr Clin Pharmacol. 2016;11:110\u20137.","journal-title":"Curr Clin Pharmacol"},{"key":"26_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.","journal-title":"PLoS Biol"},{"key":"26_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","volume":"10","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Cagnetti C, et al. Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis. CNS Drugs. 2018;10:905\u201316.","journal-title":"CNS Drugs"},{"key":"26_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0006-8993(91)90053-X","volume":"544","author":"K Lutfy","year":"1991","unstructured":"Lutfy K, Chang SC, Candido J, et al. Modification of morphine-induced analgesia and toxicity by pertussis toxin. Brain Res. 1991;544:191\u20135.","journal-title":"Brain Res"},{"key":"26_CR26","first-page":"103","volume":"103","author":"P Morales","year":"2017","unstructured":"Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids-a complex picture. Prog Chem Org Nat Prod. 2017;103:103\u201331.","journal-title":"Prog Chem Org Nat Prod"},{"issue":"12","key":"26_CR27","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s00216-017-0256-3","volume":"409","author":"EM Mudge","year":"2017","unstructured":"Mudge EM, Murch SJ, Brown PN. Leaner and greener analysis of cannabinoids. Anal Bioanal Chem. 2017;409(12):3153\u201363.","journal-title":"Anal Bioanal Chem"},{"key":"26_CR28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","volume":"299","author":"S Nissen","year":"2008","unstructured":"Nissen S, Nicholls S, Wolski K, et al. Effect of Rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. JAMA. 2008;299:1547\u201360.","journal-title":"JAMA"},{"key":"26_CR29","first-page":"497","volume":"192","author":"JP O\u2019Callaghan","year":"1975","unstructured":"O\u2019Callaghan JP, Holtzman SG. Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. J Pharmacol Exp Therap. 1975;192:497\u2013505.","journal-title":"J Pharmacol Exp Therap"},{"key":"26_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.yebeh.2016.11.012","volume":"70","author":"BK O'Connell","year":"2017","unstructured":"O'Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2017;70:341\u20138.","journal-title":"Epilepsy Behav"},{"key":"26_CR31","first-page":"1112","volume":"269","author":"R Pacifici","year":"1984","unstructured":"Pacifici R, Patrini G, Venier I, et al. Effect of morphine and methadone acute treatment on immunological activity in mice: pharmacokinetic and pharmacodynamic correlates. J Pharmacol Exp Ther. 1984;269:1112\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"26_CR32","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","volume":"147","author":"RG Pertwee","year":"2006","unstructured":"Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147:S163\u201371.","journal-title":"Br J Pharmacol"},{"key":"26_CR33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","volume":"47","author":"RD Porsolt","year":"1978","unstructured":"Porsolt RD, Anton G, Blavet N, et al. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 1978;47:379\u201391.","journal-title":"Eur J Pharmacol"},{"key":"26_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11910-018-0859-x","volume":"18","author":"J Rice","year":"2018","unstructured":"Rice J, Cameron M. Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep. 2018;18:50.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"26_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/dta.1529","volume":"6","author":"PJ Robson","year":"2014","unstructured":"Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal. 2014;6:24\u201330.","journal-title":"Drug Test Anal"},{"key":"26_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrd3673","volume":"11","author":"BP Roques","year":"2012","unstructured":"Roques BP, Fourni\u00e9-Zaluski MC, Wurm M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov. 2012;11:292\u2013310.","journal-title":"Nat Rev Drug Discov"},{"key":"26_CR37","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","volume":"163","author":"ER Russo","year":"2011","unstructured":"Russo ER. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344\u201364.","journal-title":"Br J Pharmacol"},{"key":"26_CR38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00213-002-1348-z","volume":"165","author":"ER Russo","year":"2003","unstructured":"Russo ER, McPartland JM. Cannabis is more than simply delta-9-tetrahydrocannabinol. Psychopharmacology. 2003;165:431\u20132.","journal-title":"Psychopharmacology"},{"key":"26_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF00428203","volume":"85","author":"L Steru","year":"1985","unstructured":"Steru L, Chermat R, Thierry R. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology. 1985;85:367\u201370.","journal-title":"Psychopharmacology"},{"key":"26_CR40","first-page":"61","volume":"103","author":"SE Turner","year":"2017","unstructured":"Turner SE, Williams CM, Iversen L, et al. Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. 2017;103:61\u2013101.","journal-title":"Prog Chem Org Nat Prod"},{"key":"26_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.drugalcdep.2007.11.017","volume":"94","author":"RE Vann","year":"2008","unstructured":"Vann RE, Gamage TF, Warner JA, et al. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend. 2008;94:191\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"26_CR42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00213-006-0356-9","volume":"186","author":"SA Varvel","year":"2006","unstructured":"Varvel SA, Wiley JL, Yang R, et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology. 2006;186:226\u201334.","journal-title":"Psychopharmacology"},{"key":"26_CR43","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jpain.2015.07.014","volume":"16","author":"MA Ware","year":"2015","unstructured":"Ware MA, Wang T, Shapiro S, et al. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;16:1233\u201342.","journal-title":"J Pain"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-020-00026-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-020-00026-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-020-00026-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T23:06:53Z","timestamp":1620688013000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcannabisresearch.biomedcentral.com\/articles\/10.1186\/s42238-020-00026-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1186\/s42238-020-00026-0","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All studies were performed with the approval of the University of British Columbia Animal Care Committee and were conducted and reported according to ARRIVE guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Cannevert Therapeutics is strictly a research organization and is a wholly owned subsidiary of Veritas Pharma. Cannevert Therapeutics does not produce any products for sale or generate revenue. A Material Transfer Agreement was signed with CanniMed Ltd. to use their materials for not-for-profit research purposes. Neither CanniMed nor Veritas Pharma had input on any part of the study, decision to publish, or approval of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}